Degenerative Arthritis
Conditions
Keywords
Cell mediated gene therapy, Osteoarthritis, Fibrin-glue, Degenerative Arthritis
Brief summary
The purpose of this study is to determine whether TissueGene-C, allogeneic human chondrocytes expressing Transforming Growth Factor(TGF)-b1, mixed with fibrin-glue is effective and safe in patients with degenerative arthritis.
Detailed description
TissueGene-C is a biological new drug which consists of non-transduced chondrocytes and transduced chondrocytes that express TGF-b1 to regenerate the damaged cartilage. During the clinical trial Phase 2, the investigators compare low dose or high dose TissueGene-C in 12 - months trial with 18 outpatients who have degenerative arthritis. The patients are randomized to two dose levels of TissueGene-C by 1:1 ratio, and they are monitored and recorded for alleviating symptoms, sports activities, function of the knee, and the presence of adverse events.
Interventions
BIOLOGICALTissueGene-C (Low dose)
TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue
BIOLOGICALTissueGene-C (High dose)
TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
Sponsors
Kolon Life Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female or male aged 18 years or more 2. Diagnosed with degenerative arthritis of the knee 3. With an IKDC score of 60 or lower at the screening visit 4. With a BMI of higher than18.5 and lower than 30 5. With an International Cartilage Repair Society(ICRS) Grade IV cartilage damage in the major lesions, as confirmed through an MRI scan 6. With major lesions concentrated in one section of the knee, and with the major lesions considered the main cause of the clinical symptoms 7. With major lesions defect size 2 cm2 \ 10cm2 8. With no alleviation of the symptoms even after at least three months of non-surgical treatment 9. Healthy, with no major findings from the physical examination, hematology, serum chemistry, and urine tests, and no significant medical history 10. Agreed to use an effective contraceptive method during the study period 11. Voluntarily agreed to participate in this study, and signed the informed consent form
Exclusion criteria
1. Showed clinically significant hematology, serum chemistry, and urine test results at the screening visit 2. Mechanical axis (HKA) is greater than 5° 3. Patients receiving injections to the treated knee within 2 months prior to study entry 4. Patients who are pregnant or currently breast-feeding children 5. With another joint disease (e.g., inflammatory arthritis, infectious arthritis) 6. With an infectious disease, including HIV or hepatitis 7. With any of the following clinically significant diseases: * heart disease \[e.g., myocardial infarction, arrhythmia, other serious heart diseases, * kidney disease (e.g., chronic renal failure, glomerulonephritis) * liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease) * endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease) * insulin-dependent diabetes mellitus * medical history of past or current malignant tumor * In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests: * Leukemia (White Blood Cell level in the hematology) * Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma(Alkaline phosphatase level in the hematology) 8. Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study 9. Considered inappropriate by the investigator for participation in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in IKDC Subjective Knee Evaluation | Week 0 and 48 | Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in KOOS scores | Week 0, 24 and 48 | Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS) |
| Changes in 100 mm-VAS | Week 0, 24 and 48 | Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS) |
| Comparative Evaluation of Knee Magnetic Resonance Images (MRIs) | Week 0, 24 and 48 | Comparison of pre-procedure MRI scans to those obtained at pre-dosing and at months 6 and 12 by an independent radiographic reviewer |
| Changes in WOMAC scores | Week 0, 24 and 48 | Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC) |
| Changes in IKDC Subjective Knee Evaluation | Week 0 and 24 | Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC) |
| Changes in KOOS QOL Sub-scale scores | Week 0, 24 and 48 | — |
| Proportion of Patients Use of Rescue Medication | Week 12, 24 and 48 | — |
| Changes in ICRS Cartilage Repair Assessment | week 0 and 48 | — |
Countries
South Korea
Outcome results
None listed